Market Research Hub

Global Cancer Monoclonal Antibody Partnering, Deal Trends and Financial Agreements During 2010-2017 Analyzed by Active Players

Report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.


Albany, NY -- (SBWIRE) -- 05/19/2017 -- The latest discoveries in medical technology are using certain antibodies for Cancer prevention. A lot of researches are conducting to create monoclonal antibodies that are able to cure various diseases. One of the most deadly diseases like Cancer is currently on the target for several companies and their combined efforts have aided individuals all over the world to prevent and treat life-threatening forms of Cancer. Market Research Hub (MRH) has broadcasted a latest study on the deal trends and partnering by the world's leading healthcare companies, which is titled as "Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2017: Deal trends, players, financials and forecasts". The study also provides a comprehensive listing of the top 25 most active companies in Cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of Cancer monoclonal antibody deals, as well as contract documents available in the public domain.

Request Free Sample Report :

Cancer is a growing field, because of the globally aging population, rising rates of obesity and sun exposure in the developed world and rising smoking rates in the developing world. This makes it an attractive proposition for drug developers because it has large areas of unmet medical need. The research has identified that monoclonal antibodies are widely used for the various types of Cancers. Each antibody is designed to seek out specific cells and a number of monoclonal antibodies are already in use treating Cancers, while others are in development or undergoing clinical trials.

In current dealmaking, Cancer is the most active area, and this has been reflected in monoclonal antibody dealmaking over the last 10 years or so. This report offers comprehensive details of the latest antibody agreements declared in the healthcare sectors, covering Monoclonal antibodies, Murine mAb, Chimeric mAb, Human aAb, Humanized mAb. Also, the study offers an understanding and access to the Cancer monoclonal antibody partnering deals and agreements entered into by the world's leading healthcare companies. With the constant efforts of healthcare companies, the market is driving an increase in the number of Cancer monoclonal antibody deals, which rose by almost a fifth in 2011.

Browse Full Report with TOC -

Moving further, the next chapter provides a detailed review of partnering deals signed and announced since Jan 2010. Deals are listed by headline value, signed by big pharma and most active Cancer monoclonal antibody dealmaking companies. Each deal title has been linked via Weblink to an online version of the deal record, the contract document, providing easy access to each contract document on demand. Furthermore, the report provides a synopsis of the trends in Cancer monoclonal antibody since 2010, including details of average headline, upfront, milestone and royalty terms.

About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH's expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free : 866-997-4948 (US-Canada)
Tel : +1-518-621-2074
Email :
Website :